EXT-608 is under clinical development by Extend Biosciences and currently in Phase I for Hypoparathyroidism. According to GlobalData, Phase I drugs for Hypoparathyroidism have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how EXT-608’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EXT-608 overview
EXT-607 is under development for the treatment of hypoparathyroidism. It is administered subcutaneously and acts by targeting parathyroid hormone 1 and 2 receptor. The drug candidate is a long-acting version of PTH (1-34) and is developed using D-VITylation platform technology that improves the pharmacokinetic properties of peptides and proteins by fusing with Vitamin-D.
Extend Biosciences overview
Extend Biosciences is a biotechnology company that develops novel drug for the development of peptides and proteins. The company’s pipeline products include EXT607, a long-acting parathyroid hormone; EXT418, a long-acting ghrelin peptide; EXT307 and EXT705. Extend Biosciences D-VITylation platform improves the circulating half-life and bioavailability of peptides and proteins, enabling the development potent and specific drugs. It develops products to treat patients suffering with hypoparathyroidism, metabolic cachexia, cardio pulmonary and diabetes. Extend Biosciences is headquartered in Boston, Massachusetts, the US.
For a complete picture of EXT-608’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
